Chinese biotech firm Binhui secures $93m Series C led by Temasek’s Vertex Ventures, others
Photo: Pixabay
February 10, 2021
Gene-focused biotechnology player Wuhan Binhui Biotech on Wednesday announced the completion of a 600 million yuan ($93 million) Series C round funding jointly led by healthcare-focussed Share Capital, Temasek’s Vertex Ventures China, Qianhai FOF, and CICC Capital’s sub-fund.
Returning investor Beijing Lapam Capital Management re-upped in the latest round, Binhui Biotech said in a WeChat post. Lapam had partnered Fortune Capital to seed 26.5 million yuan ($4 million) in Binhui in 2017. In 2018, Lapam exclusively poured 20 million yuan ($3 million) into the company.
With the latest Series C proceeds, Binhui expects to fund clinical trials, pipelines, and R&D platform advancements.